#5598 multicenter study to assess the frequency of adverse events from vaccination against sars-cov2 in patients with pauci-immune glomerulonephritis

Abstract Background and Aims The present study aims to investigate the frequency of adverse events of SARS-CoV2 vaccination in patients with pauci-immune glomerulonephritis. Method Patients with pauci-immune glomerulonephritis who were vaccinated with the SARS-CoV2 vaccine were retrospectively studied. Patients who had reached end-stage kidney disease before the vaccine were excluded. The histopathological diagnosis of pauci-immune glomerulonephritis, immunosuppressive regimens, resulting outcome, timing, doses, adverse effects of the vaccine and its potential effect on the clinical course of pauci-immune glomerulonephritis were recorded. Results To date, 67 patients with pauci-immune glomerulonephritis with a mean age of 59.6 (±17.5) years have been included in the study, of whom 36 (53.7%) were females. 34 (50.7%) of the patients had a medical history of arterial hypertension and 16 (23.9%) of diabetes mellitus with an average duration of 9 and 10 years respectively. 66 (98.5%) received induction therapy and 87.7% achieved remission. 50 (74.6%) received maintenance therapy and 50 (94.3%) were vaccinated against SARS-CoV2 at a mean time of 79.5 (±70.8) months from diagnostic biopsy with 3.2 (± 1.0) doses. 90% of patients were in remission and 44% were receiving immunosuppressive therapy at the time of vaccination. 26% of patients reported systemic adverse events related to vaccination and 62% local reactions at the administration site. 2 (4.3%) patients experienced pauci-immune glomerulonephritis relapse with a mean time to relapse of 5.7 (±3.4) months from the 1st dose. Conclusion Based on the results from this cohort of patients with pauci-immune glomerulonephritis, the SARS-CoV2 vaccine appears safe, with no significant impact on the likelihood of pauci-immune glomerulonephritis relapse for patients in remission.